CliffBio
small molecule

DEPAKOTE

DIVALPROEX SODIUM

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEPAKOTE
Active ingredientDIVALPROEX SODIUM
StrengthEQ 500MG VALPROIC ACID
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 1983
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEPAKOTE patent cliff — loss of exclusivity — | CliffBio